Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Protagonist Therapeutics Inc (NQ: PTGX ) 44.98 +0.61 (+1.37%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Protagonist Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 Next > PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today October 11, 2021 Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies. Via InvestorPlace Exposures Product Safety Protagonist Stock Flashes This Positive Signal After FDA Lifts Hold On Blood Diseases Drug October 11, 2021 Protagonist Therapeutics can now restart dosing patients in its rusfertide studies. Via Investor's Business Daily Exposures Product Safety Protagonist Shares Almost Double As FDA Lifts Clinical Hold On Rusfertide Program October 11, 2021 The FDA has removed the full clinical hold on Protagonist Therapeutics Inc's (NASDAQ: PTGX) rusfertide clinical studies. The Company provided the... Via Benzinga Exposures Product Safety 12 Health Care Stocks Moving In Monday's Pre-Market Session October 11, 2021 Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at... Via Benzinga Battered Protagonist Therapeutics Stock Is Primed For a Dip-Buy October 05, 2021 When Wall Street overreacts to a news catalyst, contrarian traders can step in to take advantage of a rare opportunity now with PTGX stock. Via InvestorPlace 58 Biggest Movers From Yesterday September 24, 2021 Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80 on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362... Via Benzinga PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm September 22, 2021 From Bragar Eagel & Squire, P.C. Via Business Wire The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs September 22, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... Via Benzinga 20 Stocks Moving in Wednesday's Pre-Market Session September 22, 2021 Gainers Marin Software Incorporated (NASDAQ: MRIN) rose 70.1% to $9.68 in pre-market trading following an announcement from management that the company entered into a revenue... Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session September 21, 2021 Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 30.95% to $8.08 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... Via Benzinga 32 Stocks Moving In Tuesday's Mid-Day Session September 21, 2021 Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 177.4% to $39.83. Helbiz Media, the media arm of Helbiz announced a deal with Amazon Italy, a unit of Amazon.com. ReWalk... Via Benzinga 48 Biggest Movers From Yesterday September 21, 2021 Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized... Via Benzinga The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data September 21, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... Via Benzinga Exposures COVID-19 Why Protagonist Therapeutics Stock Plunged Today September 20, 2021 The FDA has placed a clinical hold on testing of rusfertide. Via The Motley Fool Exposures Product Safety Mid-Afternoon Market Update: Dow Tumbles 2.5%; BeyondSpring Shares Plunge September 20, 2021 Toward the end of trading Monday, the Dow traded down 2.57% to 33,696.98 while the NASDAQ fell 3.14% to 14,572.25. The S&P also fell, dropping 2.58% to 4,318.67. The U.S. has... Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Monday's Intraday Session September 20, 2021 Gainers Atea Pharmaceuticals (NASDAQ:AVIR) shares increased by 13.83% to $29.86 during Monday's regular session. Trading volume for this security as of 12:30 EST is 3.... Via Benzinga What 5 Analyst Ratings Have To Say About Protagonist Therapeutics September 20, 2021 Protagonist Therapeutics (NASDAQ:PTGX) has observed the following analyst ... Via Benzinga Mid-Day Market Update: Crude Oil Down 2%; Synlogic Shares Spike Higher September 20, 2021 Midway through trading Monday, the Dow traded down 1.51% to 34,063.71 while the NASDAQ fell 2.13% to 14,723.20. The S&P also fell, dropping 1.64% to 4,360.41. The U.S. has the... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities 35 Stocks Moving In Monday's Mid-Day Session September 20, 2021 Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. (NASDAQ: EDSA) jumped 30.6% to $7.68 after the company... Via Benzinga Mid-Morning Market Update: Markets Open Lower; Brooks Automation Divests Semiconductor Business For $3B September 20, 2021 Following the market opening Monday, the Dow traded down 1.42% to 34,093.46 while the NASDAQ fell 1.86% to 14,763.93. The S&P also fell, dropping 1.54% to 4,364.65. The U.S.... Via Benzinga Topics Stocks Exposures US Equities Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2021 September 20, 2021 Upgrades For Methanex Corp (NASDAQ: Via Benzinga 48 Biggest Movers From Friday September 20, 2021 Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... Via Benzinga PTGX Stock: Why Protagonist Therapeutics Is Plunging 60% Today September 17, 2021 Today, investors in Protagonist Therapeutics and PTGX stock have seen an absolutely massive decline due to an FDA hold of its clinical trial. Via InvestorPlace Exposures Product Safety Mid-Afternoon Market Update: Nasdaq Down 1%; Protagonist Therapeutics Shares Plummet September 17, 2021 Toward the end of trading Friday, the Dow traded down 0.47% to 4,587.22 while the NASDAQ fell 1.05% to 15,023.11. The S&P also fell, dropping 0.85% to 4,435.65. The U.S. has... Via Benzinga Topics Stocks Exposures US Equities Why Protagonist Therapeutics Stock Is Tanking Today September 17, 2021 The FDA put a clinical hold on one of the biotech's new drug candidates. Via The Motley Fool Exposures Product Safety 12 Health Care Stocks Moving In Friday's Intraday Session September 17, 2021 Gainers Corvus Pharmaceuticals (NASDAQ:CRVS Via Benzinga Mid-Day Market Update: Crude Oil Falls Over 1%; Helbiz Shares Spike Higher September 17, 2021 Midway through trading Friday, the Dow traded down 0.51% to 34,572.50 while the NASDAQ fell 0.78% to 15,062.99. The S&P also fell, dropping 0.72% to 4,441.64. The U.S. has the... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities Highly Rated Protagonist Stock Takes A Hit After Study Mice Develop Tumors September 17, 2021 Mice in Protagonist's study developed tumors under their skin. Via Investor's Business Daily Exposures Product Safety Mid-Morning Market Update: Markets Down; US Consumer Sentiment Edges Higher September 17, 2021 Following the market opening Friday, the Dow traded down 0.37% to 34,622.25 while the NASDAQ fell 0.58% to 15,094.19. The S&P also fell, dropping 0.55% to 4,449.03. The U.S.... Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Friday's Pre-Market Session September 17, 2021 Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 53.98% to $3.48 during Friday's pre-market session. The company's market cap stands at $147.6... Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.